• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Eur Arch Otorhinolaryngol . Epidemiological, otolaryngological, olfactory and gustatory outcomes according to the severity of COVID-19: a study of

tetano

Editor, Senior Moderator
Eur Arch Otorhinolaryngol


. 2021 Jan 16.
doi: 10.1007/s00405-020-06548-w. Online ahead of print.
Epidemiological, otolaryngological, olfactory and gustatory outcomes according to the severity of COVID-19: a study of 2579 patients


Jerome R Lechien[SUP] #[/SUP][SUP] 1 2 3 4 [/SUP], Carlos M Chiesa-Estomba[SUP] #[/SUP][SUP] 5 6 [/SUP], Liugi A Varia[SUP] 7 [/SUP], Giacomo De Riu[SUP] 7 [/SUP], Giovanni Cammaroto[SUP] 5 8 [/SUP], Younes Chekkoury-Idrissi[SUP] 9 [/SUP], Marta Circiu[SUP] 9 [/SUP], Lea Distinguin[SUP] 9 [/SUP], Fabrice Journe[SUP] 10 [/SUP], Christophe de Terwangne[SUP] 11 [/SUP], Shahram Machayekhi[SUP] 11 [/SUP], Maria R Barillari[SUP] 5 12 [/SUP], Christian Calvo-Henriquez[SUP] 13 [/SUP], St?phane Hans[SUP] #[/SUP][SUP] 9 [/SUP], Sven Saussez[SUP] #[/SUP][SUP] 5 10 14 [/SUP]



Affiliations

Abstract

Objective: To investigate prevalence and epidemiological and clinical factors associated with olfactory dysfunction (OD) and gustatory dysfunction (GD) in COVID-19 patients according to the disease severity.
Study design: Cross-sectional study.
Methods: A total of 2579 patients with a positive diagnosis of COVID-19 were identified between March 22 and June 3, 2020 from 18 European hospitals. Epidemiological and clinical data were extracted. Otolaryngological symptoms, including OD and GD, were collected through patient-reported outcome questionnaire and Sniffin'Sticks tests were carried out in a subset of patients.
Results: A total of 2579 patients were included, including 2166 mild (84.0%), 144 moderate (5.6%) and 269 severe-to-critical (10.4%) patients. Mild patients presented an otolaryngological picture of the disease with OD, GD, nasal obstruction, rhinorrhea and sore throat as the most prevalent symptoms. The prevalence of subjective OD and GD was 73.7 and 46.8%, and decreases with the severity of the disease. Females had higher prevalence of subjective OD and GD compared with males. Diabetes was associated with a higher risk to develop GD. Among the subset of patients who benefited from psychophysical olfactory evaluations, there were 75 anosmic, 43 hyposmic and 113 normosmic patients. The prevalence of anosmia significantly decreased with the severity of the disease. Anosmia or hyposmia were not associated with any nasal disorder, according to SNOT-22.
Conclusion: OD and GD are more prevalent in patients with mild COVID-19 compared with individuals with moderate, severe or critical diseases. Females might have a higher risk of developing OD and GD compared with males.

Keywords: Anosmia; COVID-19; Clinical; Coronavirus; Epidemiological; Hyposmia; Olfactory; Outcome; SARS-CoV-2; Smell.
 
Back
Top Bottom